{
  "success": true,
  "pagesUsed": [
    0,
    1,
    2,
    3,
    4,
    5,
    6,
    7,
    8,
    14,
    18,
    19,
    22,
    25,
    26,
    44,
    50,
    53,
    54,
    58
  ],
  "modelUsed": "claude-opus-4-5",
  "confidence": 1.0,
  "documentStructure": {
    "documentContentReferences": [
      {
        "id": "ref_1",
        "name": "Protocol History Reference",
        "instanceType": "DocumentContentReference",
        "sectionNumber": "10.6",
        "sectionTitle": "Protocol Amendment History",
        "description": "Reference to protocol history including all previous amendments"
      },
      {
        "id": "ref_2",
        "name": "Study Schema Reference",
        "instanceType": "DocumentContentReference",
        "sectionNumber": "1.2",
        "sectionTitle": "Schema",
        "description": "Reference to schematic of the study design"
      },
      {
        "id": "ref_3",
        "name": "Schedule of Activities Reference",
        "instanceType": "DocumentContentReference",
        "sectionNumber": "1.3",
        "sectionTitle": "Schedule of Activities",
        "description": "Reference to Schedule of Activities (SoA)"
      },
      {
        "id": "ref_4",
        "name": "End of Study Definition Reference",
        "instanceType": "DocumentContentReference",
        "sectionNumber": "4.4",
        "sectionTitle": "End of Study/Study Completion Definition",
        "description": "Reference to end of study definition"
      },
      {
        "id": "ref_5",
        "name": "Neurological Assessment Reference",
        "instanceType": "DocumentContentReference",
        "sectionNumber": "8.3.2",
        "sectionTitle": "Neurological Assessments",
        "description": "Reference to targeted neurological assessments for PML monitoring"
      },
      {
        "id": "ref_6",
        "name": "Informed Consent Requirements Reference",
        "instanceType": "DocumentContentReference",
        "sectionNumber": "10.1.3",
        "sectionTitle": "Informed Consent Requirements",
        "description": "Reference to informed consent requirements description"
      },
      {
        "id": "ref_7",
        "name": "Rescreening Reference",
        "instanceType": "DocumentContentReference",
        "sectionNumber": "5.4",
        "sectionTitle": "Screening",
        "description": "Reference to rescreening circumstances"
      },
      {
        "id": "ref_8",
        "name": "Concomitant Therapy Reference",
        "instanceType": "DocumentContentReference",
        "sectionNumber": "6.8.3",
        "sectionTitle": "Concomitant Therapy",
        "description": "Reference to concomitant therapy requirements for vitamin E, TZDs, and GLP-1 RA"
      },
      {
        "id": "ref_9",
        "name": "Investigator's Brochure Reference",
        "instanceType": "DocumentContentReference",
        "sectionNumber": "IB",
        "sectionTitle": "Investigator's Brochure",
        "description": "Reference to latest version of ontamalimab IB for benefit/risk assessment"
      },
      {
        "id": "ref_10",
        "name": "Table 1 Reference",
        "instanceType": "DocumentContentReference",
        "sectionNumber": "1.3.1",
        "sectionTitle": "Schedule of Activities: Screening Period",
        "description": "Reference to Table 1 Schedule of Study Activities: Screening Period (Visit 1 and 2)"
      },
      {
        "id": "ref_11",
        "name": "Table 2 Reference",
        "instanceType": "DocumentContentReference",
        "sectionNumber": "1.3.1",
        "sectionTitle": "Schedule of Activities: Screening Period",
        "description": "Reference to Table 2 Schedule of Activities: Screening Period (Visit 4a and 4a2)"
      },
      {
        "id": "ref_12",
        "name": "Table 3 Reference",
        "instanceType": "DocumentContentReference",
        "sectionNumber": "1.3.2",
        "sectionTitle": "Schedule of Activities: Treatment Period, Follow-up, and End of Study",
        "description": "Reference to Table 3 Schedule of Activities: Treatment Period, Follow-up, and End of Study"
      },
      {
        "id": "ref_13",
        "name": "Figure 1 Reference",
        "instanceType": "DocumentContentReference",
        "sectionNumber": "1.2",
        "sectionTitle": "Study Schema",
        "description": "Reference to Figure 1 Study Schema"
      },
      {
        "id": "ref_14",
        "name": "Figure 2 Reference",
        "instanceType": "DocumentContentReference",
        "sectionNumber": "Figure 2",
        "sectionTitle": "Abnormal Liver-associated Test Results",
        "description": "Reference to algorithm for study drug discontinuation"
      },
      {
        "id": "ref_15",
        "name": "Figure 3 Reference",
        "instanceType": "DocumentContentReference",
        "sectionNumber": "Figure 3",
        "sectionTitle": "Flow Diagram for Quarterly Neurological Assessments",
        "description": "Reference to neurological assessment flow diagram"
      },
      {
        "id": "ref_16",
        "name": "Table 4 Reference",
        "instanceType": "DocumentContentReference",
        "sectionNumber": "Table 4",
        "sectionTitle": "Common Excluded Treatments",
        "description": "Reference to common excluded treatments table"
      },
      {
        "id": "ref_17",
        "name": "Table 5 Reference",
        "instanceType": "DocumentContentReference",
        "sectionNumber": "Table 5",
        "sectionTitle": "Neurological Assessment Plan",
        "description": "Reference to neurological assessment plan table"
      },
      {
        "id": "ref_18",
        "name": "Table 6 Reference",
        "instanceType": "DocumentContentReference",
        "sectionNumber": "Table 6",
        "sectionTitle": "Protocol-required Laboratory Tests",
        "description": "Reference to protocol-required laboratory tests"
      }
    ],
    "commentAnnotations": [
      {
        "id": "annot_1",
        "text": "Maximum allowed time between historical liver biopsy and first dose of study drug is 34 weeks for any participant, except for the participants who test positive for SARS-CoV-2 at screening",
        "annotationType": "Clarification",
        "instanceType": "CommentAnnotation",
        "sourceSection": "Screening Period",
        "pageNumber": 4
      },
      {
        "id": "annot_2",
        "text": "Progression of screening is contingent on successful confirmation of eligibility along with the sponsor's approval",
        "annotationType": "Note",
        "instanceType": "CommentAnnotation",
        "sourceSection": "Screening Period",
        "pageNumber": 4
      },
      {
        "id": "annot_3",
        "text": "In case of positive test for SARS-CoV-2 infection, screening may be paused for an additional 2 weeks (ie, screening period of up to 12 weeks)",
        "annotationType": "Clarification",
        "instanceType": "CommentAnnotation",
        "sourceSection": "Screening Period",
        "pageNumber": 4
      },
      {
        "id": "annot_4",
        "text": "The screening period can be extended by 2 weeks for any reason (including but not limited to a repeat test requirement for select and predefined measurements) on a case-by-case basis with the sponsor's approval",
        "annotationType": "Clarification",
        "instanceType": "CommentAnnotation",
        "sourceSection": "Screening Period",
        "pageNumber": 4
      },
      {
        "id": "annot_5",
        "text": "An individual who has been designated a screen failure may be rescreened once",
        "annotationType": "Note",
        "instanceType": "CommentAnnotation",
        "sourceSection": "Screen Failures",
        "pageNumber": 5
      },
      {
        "id": "annot_6",
        "text": "Not more than four participants with F1 fibrosis will be enrolled in this study",
        "annotationType": "Note",
        "instanceType": "CommentAnnotation",
        "sourceSection": "Overall Design",
        "pageNumber": 6
      },
      {
        "id": "annot_7",
        "text": "An adverse event (AE) is defined as any untoward medical occurrence in a clinical investigation participant who has signed informed consent to participate in a study; it does not necessarily have to have a causal relationship with the treatment",
        "annotationType": "Clarification",
        "instanceType": "CommentAnnotation",
        "sourceSection": "Definition of Adverse Event",
        "pageNumber": 6
      },
      {
        "id": "annot_8",
        "text": "Samples for immunogenicity should be collected when worsening of a disease is reported as an AE",
        "annotationType": "Note",
        "instanceType": "CommentAnnotation",
        "sourceSection": "Study Assessments and Procedures",
        "pageNumber": 8
      },
      {
        "id": "annot_9",
        "text": "This document is a confidential communication of Takeda. Acceptance of this document constitutes the agreement by the recipient that no information contained herein will be published or disclosed without written authorization from Takeda",
        "annotationType": "Note",
        "instanceType": "CommentAnnotation",
        "sourceSection": "Cover Page",
        "pageNumber": 2
      }
    ],
    "studyDefinitionDocumentVersions": [
      {
        "id": "ver_1",
        "versionNumber": "Amendment 3",
        "status": "Final",
        "instanceType": "StudyDefinitionDocumentVersion",
        "versionDate": "2023-09-18",
        "description": "Global amendment to revise inclusion and exclusion criteria to improve study feasibility, clarify screening period eligibility and extension of its duration, and clarify acceptable conditions for including SARS-CoV-2-infected participants",
        "amendmentNumber": "Amendment 3"
      },
      {
        "id": "ver_2",
        "versionNumber": "Amendment 2",
        "status": "Final",
        "instanceType": "StudyDefinitionDocumentVersion",
        "versionDate": "2023-04-25",
        "description": "Global amendment - previous version",
        "amendmentNumber": "Amendment 2"
      },
      {
        "id": "ver_3",
        "versionNumber": "Amendment 1",
        "status": "Final",
        "instanceType": "StudyDefinitionDocumentVersion",
        "versionDate": "2022-12-15",
        "description": "Global amendment - previous version",
        "amendmentNumber": "Amendment 1"
      },
      {
        "id": "ver_4",
        "versionNumber": "Initial version",
        "status": "Final",
        "instanceType": "StudyDefinitionDocumentVersion",
        "versionDate": "2022-11-02",
        "description": "Initial protocol version - Global"
      }
    ],
    "summary": {
      "referenceCount": 18,
      "annotationCount": 9,
      "versionCount": 4
    }
  }
}